Illinois Municipal Retirement Fund Buys 19,779 Shares of AbbVie Inc. $ABBV

Illinois Municipal Retirement Fund increased its position in AbbVie Inc. (NYSE:ABBV) by 12.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,806 shares of the company’s stock after purchasing an additional 19,779 shares during the period. AbbVie makes up approximately 0.5% of Illinois Municipal Retirement Fund’s holdings, making the stock its 22nd biggest position. Illinois Municipal Retirement Fund’s holdings in AbbVie were worth $42,790,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ABBV. Vanguard Group Inc. grew its holdings in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC lifted its position in AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after acquiring an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank purchased a new stake in AbbVie during the 2nd quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. increased its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on ABBV. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Morgan Stanley lifted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive: AbbVie’s real‑world PHASES migraine study could expand uptake for ubrogepant (an oral migraine treatment), improving its competitive positioning in migraine care and incremental revenue potential. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Positive Sentiment: Positive: AbbVie updated its Phase 2 elezanumab study in acute cervical spinal cord injury — any favorable signals in neuroscience would bolster the pipeline and longer‑term growth optionality beyond immunology and aesthetics. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Neutral Sentiment: Neutral: Analyst coverage is shifting — some upgrades/notes frame AbbVie as a stronger value/growth combination given Rinvoq and Skyrizi momentum, which supports the longer‑term revenue thesis but may be priced in. How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story
• Neutral Sentiment: Neutral: Research/commentary expects 2026 top‑line growth from Rinvoq and Skyrizi (offsetting Humira erosion); these projections support consensus revenue targets but leave sensitivity to execution and pricing. Here’s What Will Drive AbbVie’s Top-line Growth in 2026
• Neutral Sentiment: Neutral: Coverage highlighting AbbVie as a value/attractive income stock (Zacks, Seeking Alpha mentions) can support demand from income‑oriented investors even as valuation debates continue. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Negative Sentiment: Negative: The big near‑term headwind is CMS selecting Botox for price negotiation under the Inflation Reduction Act; AbbVie filed suit against HHS challenging the move. If price controls are upheld, Botox revenue and pricing could be materially affected; the lawsuit increases regulatory uncertainty and likely pressured shares. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Negative: Reports that AbbVie is reshaping U.S. operations with Medicaid concessions and broader pricing/alignment moves (including commentary about large domestic manufacturing deals) suggest margin and access tradeoffs; these actions can depress near‑term profitability even if they support market access. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

AbbVie Price Performance

AbbVie stock opened at $220.74 on Thursday. The firm has a market capitalization of $390.12 billion, a P/E ratio of 93.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company’s 50-day moving average is $223.47 and its 200 day moving average is $220.29.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.